Across TCGA pan-cancer cohorts, LILRA5 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of LILRA5’s most consistent transcriptional readouts.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LILRA5 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LILRA5 is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.
KIRC, LUAD, and LUSC are the cancer types where LILRA5 tumor–normal differential expression is most reproducible.
RNA tumor vs normal associations by lineage
Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LILRA5 RNA (log2); positive values indicate higher expression in tumor. p-values are from the differential-expression test.